Biotechnology

Filter

Current filters:

None

Popular Filters

126 to 150 of 2556 results

NewLink earns $20 million Ebola vaccine milestone from Merck

19-02-2015

US biotech firm NewLink Genetics says it had received notification from pharma giant Merck & Co that…

BiotechnologyFinancialMerck & CoNewLink GeneticsResearchTropical diseasesVaccines

Hospira’s biosimilar Inflectra comparable to Remicade in IBD treatment

Hospira’s biosimilar Inflectra comparable to Remicade in IBD treatment

19-02-2015

Positive data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first…

BiosimilarsBiotechnologyGastro-intestinalsHospiraInflectraJohnson & JohnsonMerck & CoRemicadeResearch

Genmab inks DuoBody deal with BioNovion in the field of immuno-oncology

19-02-2015

Danish biotech company Genmab has entered into a co-development and commercialization agreement with…

BioNovionBiotechnologyDuoBodyGenmabImmunologicalsLicensingOncologyResearch

Kymab appoints Anne Hyland as chief financial officer

Kymab appoints Anne Hyland as chief financial officer

19-02-2015

Kymab, a pharma company based in Cambridge, UK, focusing on monoclonal antibodies, has appointed Anne…

BiotechnologyBoardroomKymabPharmaceuticalUK

Sales up but earnings down at SOBI in quarterly and full-year financials

Sales up but earnings down at SOBI in quarterly and full-year financials

19-02-2015

Biotech firm SOBI has reported its fourth quarter and full-year 2014 financial results showing a loss.

BiotechnologyBusiness FinanceFinancialOrfadinSobiSweden

Cell Medica starts commercial cell therapy manufacture in Germany

19-02-2015

UK-based cellular immunotherapy company Cell Medica has announced the start of commercial cell therapy…

BiotechnologyCell MedicaCytovir CMVOncologyProductionUK

US FDA expands use of Celgene’s Revlimid

18-02-2015

US biotech firm Celgene revealed that the US Food and Drug Administration has expanded the existing indication…

BiotechnologyCelgene CorpOncologyRegulationRevlimidUSA

EMA Orphan Drug status for aTyr’s Resolaris in FSHD

18-02-2015

Privately-held US biotech firm aTyr Pharma says that the European Commission has granted Orphan Drug…

ATyr PharmaBiotechnologyEuropeRare diseasesRegulationResolaris

Effective new cholesterol treatments will come at great cost to health care system, says CVS

Effective new cholesterol treatments will come at great cost to health care system, says CVS

18-02-2015

The new class of cholesterol drugs could provide successful treatment to millions of Americans, but the…

BiotechnologyCVS HealthGastro-intestinalsMarkets & MarketingPricingUSA

Positive Ph III results for Navidea’s Lymphoseek in head and neck cancer

17-02-2015

US biotech firm Navidea Biopharmaceuticals today announced positive peer-reviewed publication of results…

BiotechnologyLymphoseekNavidea BiopharmaceuticalsOncologyResearch

Australia to subsidize Genzyme’s Pompe disease drug Myozyme for young patients

Australia to subsidize Genzyme’s Pompe disease drug Myozyme for young patients

17-02-2015

Australia’s Minister for Health Sussan Ley said today that she has approved a life-saving drug that…

AustraliaBiotechnologyFinancialGenzymeHealthcareMyozymeRare diseasesSanofi

US Orphan Drug status for Bexion’s Saposin C for glioblastoma

US Orphan Drug status for Bexion’s Saposin C for glioblastoma

17-02-2015

Privately-held US biotech firm Bexion Pharmaceuticals has received Orphan Drug designation for the US…

Bexion PharmaceuticalsBiotechnologyBXQ-350OncologyRegulationSaposin CUSA

Biotie receives positive opinion on orphan drug status for BTT1023 from EMA

Biotie receives positive opinion on orphan drug status for BTT1023 from EMA

17-02-2015

Finnish biotech and pharma company Biotie has received a positive opinion from the European Medicines…

BiotechnologyBiotie TherapiesFinlandNephrology and HepatologyRegulation

Call for transitional arrangements for Australia’s R&D Tax incentive cap

Call for transitional arrangements for Australia’s R&D Tax incentive cap

17-02-2015

The passage of unwelcome legislation last week to cap claims on the Australian Research and Development…

AustraliaBiotechnologyFinancialPoliticsResearch

Angle raises $11.2 million to aid development of Parsortix cancer cell filter

Angle raises $11.2 million to aid development of Parsortix cancer cell filter

16-02-2015

UK-based medtech company Angle has raised £7.3 million ($11.2 million) through issuing new shares. It…

AngleBiotechnologyErbituxFinancialOncologyResearch

Actelion posts strong 2014 earnings growth, but sales shy of expectations

Actelion posts strong 2014 earnings growth, but sales shy of expectations

16-02-2015

Switzerland-based Actelion this morning reported financial results for full-year 2014, showing that sales…

ActelionBiotechnologyFinancialRespiratory and Pulmonary

Ono signs deal with Dako for Opdivo companion diagnostic test

Ono signs deal with Dako for Opdivo companion diagnostic test

16-02-2015

Japanese pharma company Ono Pharmaceutical and Danish diagnostic provider Dako have signed a new partnership…

BiotechnologyDakoJapanLicensingOncologyOno PharmaceuticalOpdivo

Intrexon to acquire Belgium's ActoGeniX, bringing new generation of orally-delivered biotherapeutics

13-02-2015

US synthetic biology focussed US firm Intrexon has entered into a definitive agreement to acquire ActoGeniX,…

ActoGeniXBiotechnologyIntrexonMergers & Acquisitions

Tecfidera, first-line oral treatment for multiple sclerosis, approved in India

13-02-2015

US biotech major Biogen Idec’s Indian subsidiary has received approval of the first oral therapy for…

Biogen IdecBiotechnologyIndiaNeurologicalRegulationTecfidera

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

Positive Ph III clinical trial extension results for Genzyme’s Cerdelga

13-02-2015

French pharma major Sanofi subsidiary Genzyme has reported positive extension study data from its Phase…

BiotechnologyCerdelgaGenzymeRare diseasesResearchSanofi

NICE final draft guidance does not recommend pomalidomide for blood cancer

NICE final draft guidance does not recommend pomalidomide for blood cancer

13-02-2015

The England medical costs watchdog the National Institute for Health and Care excellence (NICE) has issued…

BiotechnologyCelgene CorpImnovidOncologypomalidomidePricingRegulationUK

Strong 2014 financials from Shire, bolstered by

Strong 2014 financials from Shire, bolstered by "break fee"

12-02-2015

Shares of Ireland-headquartered Shire gained 4.6% to £49.97, after the drugmaker reported pretax profit…

BiotechnologyFinancialRare diseasesShire

AusBiotech slams government moves on R&D Tax Incentive deals

12-02-2015

The Australian government’s shock deal with the Palmer United Party and Independent Senator Xenophon…

AustraliaBiotechnologyFinancialPoliticsResearch

126 to 150 of 2556 results

Back to top